Susan Ide

Susan Ide

Susan’s Company

Novartis

Website: http://www.novartis.com

Twitter: @novartis

Novartis provides healthcare solutions that address the evolving needs of patients and societies. Focused solely on healthcare, Novartis offers a ... More » Novartis provides healthcare solutions that address the evolving needs of patients and societies. Focused solely on healthcare, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, cost-saving generic pharmaceuticals, preventive vaccines, diagnostic tools and consumer health products. Novartis is the only company with leading positions in each of these areas. In 2008, the GroupÂ’s continuing operations achieved net sales of USD 41.5 billion and net income of USD 8.2 billion. Approximately USD 7.2 billion was invested in R&D activities throughout the Group. Headquartered in Basel, Switzerland, Novartis Group companies employ approximately 99,000 full-time-equivalent associates and operate in more than 140 countries around the world. Novartis International AG is a Swiss multinational pharmaceutical company based in Basel, Switzerland, ranking number two in sales (46.806 billion US$) among the world-wide industry in 2010. Novartis manufactures such drugs as clozapine (Clozaril), diclofenac (Voltaren), carbamazepine (Tegretol), valsartan (Diovan) and imatinib mesylate (Gleevec/Glivec). Additional agents include cyclosporin (Neoral/Sandimmun), letrozole (Femara), methylphenidate (Ritalin), terbinafine (Lamisil), and others. In 1996 Ciba-Geigy merged with Sandoz, with the pharmaceutical and agrochemical divisions of both staying together to form Novartis. Other Ciba-Geigy and Sandoz businesses were sold off, or, like Ciba Specialty Chemicals, were spun off as independent companies. The Sandoz brand disappeared for 3 years, but was revived in 2003 when Novartis consolidated its generic drugs businesses into a single subsidiary and named it Sandoz. Novartis divested its agrochemical and genetically modified crops business in 2000 with the spinout of Syngenta, in partnership with AstraZeneca which also divested its agrochemical business. Novartis is a full member of the European Federation of Pharmaceutical Industries and Associations (EFPIA) the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), and the Pharmaceutical Research and Manufacturers of America (PhRMA). [ CrunchBase ]

GDS International Leads the Way for the Pharmaceutical Industry at its Upcoming NGP DD 30 Summit in...

Novartis - Included within this year’s delegation are Sibo de Jong, Vice-President Pharmaceutical R Simon Read, Vice President Michael Rotte, Biomarker Development EU Head, Novartis; Dave Gunput...

Michael Rotte

Mentioned in this article:
Michael Rotte

Drug maker Novartis loses India patent battle | The Wenatchee World

"We brought this case because we strongly believe patents safeguard innovation and encourage medical progress," said Ranjit Shahani, Vice Chairman and Managing Director, Novartis India. The ruling "will hinder medical progress for diseases without effective treatment options," he said. ...

Ranjit Shahani

Mentioned in this article:
Ranjit Shahani

Trials in Esophageal Ca, HCC Fall Short

Novartis - Note that these studies were published as abstracts and presented at a conference. These data and conclusions should be considered to be preliminary until published in a peer-reviewed journal. SAN FRANCISCO -- Patients with esophageal cancer derived no survival benefit with the addition of ...

Andrew Zhu

Mentioned in this article:
Andrew Zhu

Novartis Loses Bid To Patent New Version Of Glivec In India, Giving A Boost To Country’s $26B Generi...

" This ruling is a setback for patients that will hinder medical progress for diseases without effective treatment options ," Ranjit Shahani, vice chairman and managing director of Novartis India Limited (BOM:500672), told the BBC. The company responded to Monday’s ruling by saying it ...

Ranjit Shahani

Mentioned in this article:
Ranjit Shahani

NetConsumo: Researchers look to improve understanding of complex brain

Novartis - “We have already identified a lot of gaps in knowledge about treatments of brain diseases,” said Gordon Francis, head of the NeuroInflammation Clinical Science Unit within the NeuroScience Franchise at the Swiss pharmaceutical company Novartis. RPDC - Revista Portuguesa de Direito do ...

Gordon Francis

Mentioned in this article:
Gordon Francis

Drug Maker Novartis Loses India Patent Battle | ThirdAge

Ranjit Shahani, the vice chairman and managing director of Novartis India, said the ruling "will hinder medical progress for diseases without effective treatment options. " He said the court's decision made India an even less attractive country for major investments by international ...

2013: Few bitter pills, booster injections for pharma sector - NDTVProfit.com

Commenting on the developments, Novartis India vice chairman and managing director Ranjit Shahani told PTI, "As far as the innovator Pharma Companies were concerned they continue to face challenges on implementation of patents and threat of more compulsory licenses. " While most of the ...

Join Newsle to find out when Susan Ide makes the news.

As a Newsle member, you’ll be able to:

  • Get alerts on Susan Ide
  • See news articles & blog posts about Susan Ide
  • Follow your friends & colleagues in the news
This profile only includes publicly available information. Questions or comments? Contact Us
Freebase CC-BY
Data from Freebase, licensed under CC-BY
Source: CrunchBase
Data from Wikipedia, licensed under the GFDL